Stephen Hanauer to Biological Products
This is a "connection" page, showing publications Stephen Hanauer has written about Biological Products.
Connection Strength
3.401
-
5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959.
Score: 0.650
-
Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5.
Score: 0.426
-
Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
Score: 0.404
-
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
Score: 0.309
-
The role of biologics in ulcerative colitis. Dig Dis. 2010; 28(3):497-500.
Score: 0.305
-
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68.
Score: 0.252
-
General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
Score: 0.234
-
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
Score: 0.191
-
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
Score: 0.172
-
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. Am J Gastroenterol. 2022 08 01; 117(8):1288-1295.
Score: 0.170
-
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42.
Score: 0.132
-
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
Score: 0.127
-
Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254.
Score: 0.029